Corvus Pharmaceuticals, Inc. (CRVS) has a consensus analyst rating of Buy, based on 13 analysts covering the stock. Of those, 12 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for CRVS is $31.80, representing a +108.5% upside from the current price of $15.25. Price targets range from a low of $27.00 to a high of $42.00.
